Latest Posts
About This Stock
More About This Stock
Read
Read
AbbVie Inc. Dividend Stock Analysis - Saturday, June 22
Article By:
Dividends4Life
Saturday, June 22, 2024 3:40 PM EDT
Here are some highlights from a detailed, quantitative analysis AbbVie Inc. stock. Let's take a closer look at various factors, such as the stock's value and dividend.
Week In Review: FutureGen Sells MAb For IBD To AbbVie In $1.7 Billion Deal
Article By:
ChinaBio® Today
Saturday, June 22, 2024 12:40 PM EDT
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting protein-tyrosine kinase 7 candidate to Day One Biopharma.
5 Leading Healthcare Stocks Surging On Pent-up Demand
Just a hunch. The healthcare industry is highly regulated and Dems generally favor more regulation, making it more difficult for drugmakers to secure the necessary regulatory approvals to market new products. Regulatory changes could drastically alter a healthcare stock’s growth prospects, for instance. But I reckon I'll not sell $ABBV after holding during all the long downward spiral.
5 Leading Healthcare Stocks Surging On Pent-up Demand
Seems health stocks should do well but a #Biden presidency will not favor this sector. $ABBV $PFE
Macy’s Q1 Was Bad, But The Company Has The Cash To Survive The Current Pandemic
Glad you liked it Sheryl! Right now I think a range of REITs and healthcare stocks are attractive from a risk-reward standpoint, including $ABBV, $BMY, $O, $SLG, $SPG, etc.
AbbVie: Is This Biopharma Giant’s 6% Yield Safe?
How much debt does $ABBV have?
AbbVie Has It All: Growth, Dividend Growth And Compelling Valuation
$ABBV certainly sounds like a great buy.
AbbVie Inc. Increases Humira Prices, Receives FDA Approval For New Drug
Excited to hear the #FDA approved #IMBRUVICA. Should bode very well for $ABBV. And I think it's 8% price hike of #Humira is reasonable (though I realize those taking the drug may disagree).